Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CVM 
CEL-SCI Corp (CVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: CVM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $42.5
1 Year Target Price $42.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.39% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.08M USD | Price to earnings Ratio - | 1Y Target Price 42.5 |
Price to earnings Ratio - | 1Y Target Price 42.5 | ||
Volume (30-day avg) 1 | Beta 0.51 | 52 Weeks Range 1.98 - 32.70 | Updated Date 11/6/2025 |
52 Weeks Range 1.98 - 32.70 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -70.09% | Return on Equity (TTM) -328.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78093770 | Price to Sales(TTM) 11797.42 |
Enterprise Value 78093770 | Price to Sales(TTM) 11797.42 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.71 | Shares Outstanding 7993356 | Shares Floating 6317819 |
Shares Outstanding 7993356 | Shares Floating 6317819 | ||
Percent Insiders 8.2 | Percent Institutions 8.37 |
Upturn AI SWOT
CEL-SCI Corp
Company Overview
History and Background
CEL-SCI Corp was founded in 1983 and is focused on researching and developing immunotherapy treatments for cancer and other diseases. It has primarily focused on its Multikine immunotherapy program.
Core Business Areas
- Immunotherapy Research and Development: This segment focuses on the research, development, and potential commercialization of CEL-SCI's immunotherapy platform, primarily Multikine.
Leadership and Structure
CEL-SCI Corp's leadership team typically includes a CEO, CFO, CSO, and a board of directors. Specific names and roles can fluctuate.
Top Products and Market Share
Key Offerings
- Multikine (Leukocyte Interleukin, Injection): Multikine is CEL-SCI's lead investigational immunotherapy drug for the treatment of head and neck cancer. It is designed to boost the immune system's response to cancer cells. As it is not yet approved for sale, there is no market share data. Competitors include established treatments like chemotherapy, radiation therapy, and other immunotherapies (e.g., Keytruda, Opdivo).
Market Dynamics
Industry Overview
The immunotherapy market is a rapidly growing segment within the pharmaceutical industry, driven by advances in understanding the immune system's role in fighting cancer. There is strong interest in novel immunotherapies and combination therapies.
Positioning
CEL-SCI Corp is positioned as a clinical-stage biotechnology company focused on developing immunotherapy treatments. Its competitive advantage, if Multikine is approved, would be its approach to boosting the immune system before standard of care treatments.
Total Addressable Market (TAM)
The TAM for head and neck cancer therapeutics is estimated in the billions of dollars annually. CEL-SCI's positioning within this TAM depends on the future approval and adoption of Multikine.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Potentially synergistic with standard of care
- Dedicated research team
Weaknesses
- Lack of product approvals
- Limited financial resources
- Dependence on successful clinical trials
- History of clinical trial delays and challenges
Opportunities
- Potential FDA approval of Multikine
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer indications
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
CEL-SCI Corp faces significant competition from established pharmaceutical companies with approved cancer therapies. Its competitive advantage hinges on the clinical efficacy and market acceptance of Multikine, if approved.
Growth Trajectory and Initiatives
Historical Growth: CEL-SCI's growth has been limited to research and development progress. It lacks product revenue historically.
Future Projections: Future growth is entirely dependent on the successful commercialization of Multikine. Analyst estimates are highly speculative and vary widely.
Recent Initiatives: CEL-SCI's recent initiatives revolve around the continued pursuit of Multikine's regulatory approval and clinical trials.
Summary
CEL-SCI Corp is a high-risk, high-reward biotechnology company. Its success is entirely contingent on the approval and commercialization of Multikine. The company has limited revenue and relies heavily on fundraising. Investors should be aware of the speculative nature of the investment and the significant competition in the oncology market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- SEC filings
- Clinical trial data
- Analyst reports
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on thorough research and consultation with a financial advisor. Data may be delayed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CEL-SCI Corp
Exchange NYSE MKT | Headquaters Vienna, VA, United States | ||
IPO Launch date 1987-01-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://cel-sci.com |
Full time employees - | Website https://cel-sci.com | ||
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.